Welcome to all new joiners at IAG, Image Analysis Group!
‘I decided to join IAG because of their aim to be well rounded in imaging. IAG’s mission in collaboration drew me in. The match with our shared mission in information delivery to give people more power of their health was there,’ Isabel Ann Wingert
We are welcoming many new joiners this month!
As the covid blanket of immotion lifts, the clinical research industry accelerate to the levels we have not seen before. Almost every trial put on hold in 2019 is back in action, with better smarter design and requiring new technologies for faster access to information. The industry itself is seeing a fresh boost of energy, with nearly 50% of all trials now requiring imaging, for faster assessment of patient response and drug efficacy.
With this, we celebrate our teams! Well done to everyone who bravely stood by our clients during covid and did everything possible and impossible to speed up their trials, encouraging patients to make imaging visits and relentlessly working with the sites on getting the best possible quality image.
Our warm welcome and thanks to those you have chosen to join IAG and getting ready to dedicate their energy to our clients’ projects.
‘I am definitely looking forward to this opportunity to join an amazing team in such a fast growing and innovative company!‘, Vasavi Surisetty, joining operations team.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.
Dr Kubassova is a leading innovator and passionate investor in healthcare.
Presenting new data from Ulcerative Colitis trial at DDW 2023.